发明名称 Methods for preventing multidrug resistance in cancer cells
摘要 This invention is directed to methods for preventing the emergence of multidrug resistance in tumor cells during cancer chemotherapy. In particular, it relates to the use of protein kinase inhibitors to prevent the induction of expression of the multidrug resistance gene (MDR1) encoding P-glycoprotein by chemotherapeutic drugs. MDR1 expression, which results in tumor cell resistance to subsequent treatment with certain chemotherapeutic drugs, is shown herein to be induced in response to treatment with various cytotoxic agents, including such agents that are and are not substrates for P-glycoprotein-mediated efflux from cancer cells. Inhibitors of protein kinases, in particular, protein kinase C, are shown herein to suppress this cellular response. In addition, such protein kinase inhibitors are also shown herein to inhibit expression of a gene encoding a multidrug resistance-associated protein (the MRP gene). The instant invention provides methods for using such protein kinase inhibitors to both suppress induction of MDR1 gene expression by cytotoxic drugs, and to inhibit expression of MRP. The invention also provides methods for identifying protein kinase inhibitors that have either or both of these effects on MDR1 and MRP expression. Thus, the invention provides useful methods and reagents for preventing the emergence of multidrug resistance in tumor cells treated with cytotoxic and chemotherapeutic drugs in cancer patients undergoing chemotherapy, when such protein kinase inhibitors are administered prior to or simultaneous with cytotoxic drug treatment in such individuals.
申请公布号 US5972598(A) 申请公布日期 1999.10.26
申请号 US19950370724 申请日期 1995.01.10
申请人 BOARD OF TRUSTESS OF THE UNIVERSITY OF ILLINOIS 发明人 CHAUDHARY, PREET;SHTIL, ALEXANDER A.;RONINSON, IGOR B.
分类号 C07H15/232;A61K;A61K31/00;A61K31/495;A61K31/55;A61K31/70;A61K31/7028;A61K31/7034;A61K31/7036;A61K38/00;A61K45/00;A61K45/06;A61P35/00;B05B7/06;C12Q1/68;G01N33/50;(IPC1-7):C12Q1/68 主分类号 C07H15/232
代理机构 代理人
主权项
地址